Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 5
2005 5
2006 10
2007 5
2008 15
2009 15
2010 18
2011 22
2012 22
2013 27
2014 34
2015 33
2016 33
2017 43
2018 43
2019 76
2020 79
2021 112
2022 132
2023 128
2024 133
2025 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

908 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell and spatial architecture of primary liver cancer.
Zhou PY, Zhou C, Gan W, Tang Z, Sun BY, Huang JL, Liu G, Liu WR, Tian MX, Jiang XF, Wang H, Tao CY, Fang Y, Qu WF, Huang R, Zhu GQ, Huang C, Fu XT, Ding ZB, Gao Q, Zhou J, Shi YH, Yi Y, Fan J, Qiu SJ. Zhou PY, et al. Among authors: zhou c. Commun Biol. 2023 Nov 20;6(1):1181. doi: 10.1038/s42003-023-05455-0. Commun Biol. 2023. PMID: 37985711 Free PMC article.
APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases.
Shi R, Wang X, Wu Y, Xu B, Zhao T, Trapp C, Wang X, Unger K, Zhou C, Lu S, Buchner A, Schulz GB, Cao F, Belka C, Su C, Li M, Shu Y. Shi R, et al. Among authors: zhou c. Theranostics. 2022 May 16;12(9):4181-4199. doi: 10.7150/thno.73235. eCollection 2022. Theranostics. 2022. PMID: 35673559 Free PMC article.
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J. Zhou C, et al. J Am Acad Dermatol. 2023 Nov;89(5):911-919. doi: 10.1016/j.jaad.2023.02.063. Epub 2023 Apr 3. J Am Acad Dermatol. 2023. PMID: 37019385 Clinical Trial.
908 results